Clinical Data ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma Pharmaceutical TechnologyEarly data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca's ESOT-01.HematologyRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) Pharmaceutical Technology Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01. Hematology Read full story Post navigation Previous: ASCO26: In vivo oncology approaches continue to show promiseNext: Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026